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Abstract
Antigenic variation and viral evolution have thwarted traditional influenza vaccination strategies. 
The broad protection afforded by a “universal” influenza vaccine may come from immunogens 
that elicit humoral immune responses targeting conserved epitopes on the viral hemagglutinin 
(HA), such as the receptor-binding site (RBS). Here, we engineered candidate immunogens that 
use non-circulating, avian influenza HAs as molecular scaffolds to present the broadly neutralizing 
RBS epitope from historical, circulating H1 influenzas. These “resurfaced” HAs (rsHAs) remove 
epitopes potentially targeted by strain-specific responses in immune-experienced individuals. 
Through structure-guided optimization we improved two antigenically different scaffolds to bind a 
diverse panel of pan-H1 and H1/H3 cross-reactive bnAbs with high affinity. Subsequent 
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serological and single germinal center B cell analyses from murine prime-boost immunizations 
show that the rsHAs are both immunogenic and can augment the quality of elicited RBS-directed 
antibodies. Our structure-guided, RBS grafting approach provides candidate immunogens for 
selectively presenting a conserved viral epitope.
Graphical Abstract
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Influenza evolves primarily at the human population level and within its animal reservoirs 
(swine and avian)1. Influenza A viruses include 2 groups containing a total of 18 subtypes 
that are defined by genetic and serologic characteristics of the viral glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA). Two influenza A subtypes, H1N1 and H3N2, 
and two influenza B lineages, Victoria and Yamagata, currently cocirculate in the human 
population1. Host humoral pressure, which predominantly targets the viral HA, selects for 
influenza mutations that render previous immune responses suboptimal. The humoral 
response then evolves, through immune memory and further B cell affinity maturation2–5. 
The net effect of this on-going selection across the entire population exposed to the virus is a 
virus-immunity “arms race”. The repeated exposure to influenza in the human population 
results in preexisting immunity which influences subsequent immune responses6–11. This 
immunological memory12, 13 presents a significant hurdle towards the development of a 
“universal” influenza vaccine. Strategies that both overcome the recall of refined, strain-
specific responses and elicit broadly neutralizing antibodies (bnAbs) are necessary.
bnAbs against influenza HA target two relatively invariant epitopes - the receptor binding 
site (RBS) on the HA “head” and a surface along the HA “stem”14. While stem-directed 
immunogens are in clinical development, efforts focusing on the RBS have lagged behind14. 
A significant challenge for RBS-directed immunogens is presentation of the complex RBS 
structure that includes multiple segments, separated in linear sequence, but adjacent in 
conformational space15. While computational design of novel protein scaffolds has been 
done for HIV and RSV, the grafted epitopes were often less-complex (e.g., a single alpha-
helix)16, 17.
To overcome the significant hurdle of de novo protein design we hypothesized that the RBS 
epitope from one HA subtype could be transplantable onto another antigenically distinct 
HA. We used non-circulating, avian influenza HAs as molecular scaffolds to present the 
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RBS from circulating H1 influenzas. These resurfaced HA (rsHA) scaffolds present the H1 
conserved RBS recognized by bnAbs and alter other epitopes targeted by strain-specific 
responses in immune-experienced individuals. The crystal structure of one scaffold in 
complex with a bnAb allowed for further structure-guided optimization of two antigenically 
distinct scaffolds to bind a diverse panel of pan-H1 and H1/H3 cross-reactive bnAbs. 
Immunization with a recombinant H1 HA followed by a single, heterologous boost with our 
rsHA immunogen showed comparable levels of RBS-directed antibody response to the H1 
homologous prime-boost regimen. These data suggest that these rsHA immunogens with 
further optimization of the vaccine regimen may provide a pathway to a universal influenza 
vaccine, by exploiting the immunogenicity of the conserved RBS.
RESULTS
Grafting the H1 SI-06 RBS onto acceptor HA scaffolds.
As a proof of principle, we chose the circulating H1 RBS epitope as the basis of a donor 
graft to scaffold onto HA subtypes not currently circulating in the human population (Fig. 
1a). H1 influenzas can be grouped into roughly three antigenic clusters with prototypical 
members represented by H1 Massachusetts/1/1990 (H1 MA-90), H1 Solomon Islands/03/06 
(H1 SI-06) and H1 California/04/2009 (H1 CA-09) (Fig. 1b and Fig. S1)6. Importantly, 
bnAb have been identified that can span these antigenic clusters (e.g., CH6718, 641 I-919, 
Ab664920 and 5J821). We used the H1 SI-06 as the initial donor and defined four segments, 
S1–S4 (Fig. 1b–e), comprising the RBS epitope for grafting (Fig. 1b). These segments 
include 7 of the 13 critical residues that contact the receptor, sialic acid (Fig. 1e); these 13 
residues define the RBS “core” (Fig. S1). Many of the remaining residues not included in 
the graft (e.g., Y95 and W153) are in the base of the RBS and they are nearly invariant 
across influenza subtypes. For the initial molecular scaffolds, we selected two non-
circulating group 2 influenzas, H4N6 A/America black duck/New Brunswick/00464/2010 
(H4 NB-10) and H14N6 A/mallard/Wisconsin/10OS3941/2010 (H14 WI-10). We selected 
them because they have little sequence similarity to circulating H1s (Fig. S2). The acceptor 
HA S1-S4 boundaries were defined by aligning the H1 SI-06 sequence (Fig. 1c). The rsHAs 
have the following nomenclature: “rsH4NBvX”; the resurfaced (rs) HA scaffold subtype 
(H4), with an abbreviated strain name (NB) and different versions (vX). We could 
successfully overexpress the inter-group transfer of the H1 SI-06 RBS graft onto the H4 and 
H14 scaffolds resulting in our first generation rsH4NBv1 and rsH14WIv1 scaffolds (Fig. 
S3).
Binding affinities of bnAbs to rsHAs.
We determined the binding affinities of a panel of RBS-directed Fabs to these initial 
scaffolds by using biolayer interferometry (BLI). This panel included four pan-H1 (CH67, 
641 I-9, H2526 and H2227) and two H1/H3 cross-reactive bnAbs (K03.12 and C05) that 
engage the RBS19, 21–25. Each antibody has a footprint that overlaps with the RBS core but 
has different angles of approach and peripheral contacts (Fig. S4). As seen in Table 1, 
neither scaffold bound all the RBS-directed Fabs. rsH4NBv1 bound only K03.12 with an 
equilibrium dissociation constant (KD) ~5.2x greater than wildtype H1 SI-06. rsH14WIv1 
bound CH67, K03.12 and C05 with KDs ~17x, ~2.7x and ~1.3x greater than wildtype H1 
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SI-06. None of the antibodies bound wildtype H4 NB-10 or H14 WI-10. These data suggest 
that there are peripheral residues in the first-generation scaffolds that impede bnAb binding 
and/or that the RBS graft is being presented in an altered conformation.
Structure of rsH4NBv1 in complex with bnAb, K03.12.
To identify further modifications on the first-generation scaffold that can be engineered to 
improve affinity to the bnAb panel, we determined the crystal structure of the rsH4NBv1 
head in complex with the cross-reactive H1/H3 K03.12 antibody (Fig. 2a, Table S1). Like 
the previously characterized C05 antibody, K03.12 engages the RBS with almost exclusively 
CDR H3–dependent contacts22. The antibody contacts 14 of the 26 residues in the S1-S4 
RBS graft. Additional contacts are made with conserved residues critical for sialic acid 
interactions in the base of the RBS including Y95, W153, T155 and H183 (Fig. 2b, H3 
numbering). Comparison of the K03.12-rsH4NBv1 structure and the K03.12-H3 
Texas/50/2012 complex shows a nearly identical approach with a slight twist and rocking of 
the VH-VL towards HA about the principle axis (Figs. S5a, b)23. The contacting residues 
within the antigen-combining sites between the two structures are nearly identical (Figs. 
S5c, d). A comparison of the rsH4NBv1 HA to a wildtype H4 A/duck/Czechoslovakia/1956 
(PDB 5XL3) and wildtype H1 SI-06 (PDB 5UGY) shows a displacement about S2 (150-
loop) with a shift of ~3Å, however the overall conformation in the other grafted RBS 
segments is similar to that of the wildtype H1 SI-06 RBS (Fig. 2c).
Structure-guided improvement of the rsHA scaffolds.
To improve scaffold binding to the RBS-directed bnAb panel, we docked the previously 
determined Fab structures onto the determined rsH4NBv1 structure to identify residues that 
may be modified to either alleviate steric clashes and/or reinforce interactions. We 
engineered two additional (scaffold) versions: 1) rsH4NBv2 had three mutations K131T, 
T192R and N193A (Fig. 2d) and 2) rsH4NBv3, had four additional mutations, N145S, 
K196H, N198E and S219K (Fig. 2e); no changes were made in the original grafted 
segments. We first assayed for scaffold improvement using an enzyme-linked 
immunosorbent assay (ELISA) (Fig. 3). None of the antibodies bound to wildtype H4 
NB-10 (Fig. 3a) consistent with our BLI data using Fabs (Table 1). The second-generation 
scaffold increased affinity to four of the five Fabs (Fig. 3b, c) while the third generation, 
rsH4NBv3, resulted in high-affinity binding to all five RBS-directed antibodies (Fig. 3c). 
Based on this optimized rsH4NBv3 construct, we asked whether the same seven mutations 
could be made in context of the rsH14WIv1 scaffold to increase its affinity for the entire 
panel of RBS-directed antibodies. Indeed, when these mutations were engineered into 
rsH14WIv1 this optimized construct bound the entire panel of RBS-directed antibodies with 
high affinity (Fig. 3g–i). For reference, H1 SI-06 reactivity to the RBS-directed Ab panel is 
shown (Fig. 3i). A summary of the KDs are shown in Figs. 3e, 3j.
Finally, we tested the optimized scaffolds in BLI to obtain more accurate KDs, free of 
avidity effects present when using IgGs in ELISA. As seen in Table 1, both optimized 
scaffolds significantly increased affinities over their first-generation counterparts; rsHAs 
based on both optimized scaffolds bound all six bnAbs included in the panel. In particular, 
the rsH14WIv2 scaffold yielded affinities for CH67, H2526 and C05 even greater than those 
Bajic et al. Page 4













of wildtype H1 SI-06. In some cases (e.g., C05) the optimized resurfaced scaffold bound the 
Fab >10-fold more tightly than did wildtype H1 SI-06. In general, the rsH14WIv2 had 
affinities closest to the wildtype H1 SI-06. These data suggest a set of key residues, in 
addition to the initial RBS-donor grafts, that can be grafted onto other potential scaffolds to 
present an “optimized” epitope to bind (or elicit) a diverse set of RBS-directed bnAbs.
Serum and germinal center B cell responses to the rsHA immunogen.
To evaluate whether our rsHA immunogens can enrich for RBS-directed responses by 
allowing the expansion and differentiation of memory B cells, we first generated a knock-in 
(KI) mouse that has a human JH6 and D2–2 segments (Fig. S7 and Table S2). The human 
JH6 and D2–2 segments were chosen to mimic two key features of observed human-RBS 
directed bnAbs that are absent in the wildtype C57BL/6 murine model: 1) a poly-tyrosine 
motif in the CDR H3 loop and 2) an overall CDR H3 length of 19–20 amino acids necessary 
for engaging the RBS19. We therefore immunized these generated mice (see Methods) with 
recombinant H1 SI-06 HA, to prime humoral immunity to an H1, then boosted with our 
recombinant rsH4NBv3 (Fig. 4a). We compared the resulting serum and germinal center 
(GC) responses originating from a homologous H1 SI-06/H1 SI-06 or a heterologous H1 
SI-06/rsH4NBv3 prime/boost immunization. We found that post-boost, the serum IgG titers, 
as well as the relative serum reactivity to the initial H1 SI-06 HA were comparable between 
the two cohorts (Fig. S6a). To deconvolute the contribution of the H4 scaffold-dependent 
Abs, we performed a serum competition assay with H1 RBS-directed bnAb CH67 (Fig. 4b) 
and found no demonstrable difference between the two cohorts. At the cellular level, we 
noted that the GC B cell frequencies were ~3-fold higher in mice boosted with recombinant 
rsH4NBv3 (Fig. 4c and S8). These data potentially point to disparities in immunogenicity 
between H1 SI-06 and rsH4NBv3 and highlight the apparent immunodominance of the H4 
scaffold. To quantify the serum abundance of RBS-directed antibodies, we screened the sera 
from the two cohorts against H1 SI-06 and rsH4NBv3 HAs in a Luminex assay (Fig. 4d, e). 
Sera from the heterologous immunization reacted more strongly with rsH4NBv3 (Fig. 4e 
and S6b) and as strongly as those from the homologous one with H1 SI-06 (Fig. 4d and 
S6c). These data highlight the immunogenicity of the resurfaced HA and its potential as a 
novel antigen.
Comparison of single GC B cell responses to wild-type and resurfaced HAs.
To complement our serological study and to understand more fully HA RBS targeting, we 
assessed the reactivity of individual GC B cells isolated post immunization using our single-
cell Nojima culture system (Fig. 5). We screened the culture supernatants from each 
immunization (homologous or heterologous) against both wild-type H1 SI-06 and rsH4 
NB-10 in a competition assay with a known RBS-targeting mAb CH67 (Fig. 5a). The 
competition was performed on Luminex beads and the reduction in fluorescent signal, 
resulting from antibody competition, was expressed as % inhibition. We defined competitors 
as antibodies with 75% inhibition of CH67 mAb binding or greater. The data show that the 
homologous immunization (wild-type H1 SI-06 prime-boost) elicited 7 mAbs with such 
properties. Those mAbs competed for CH67 binding only on wild-type H1 SI-06 and not on 
rsH4 NB-10 beads, suggesting that the footprint of these antibodies on HA extends beyond 
the minimal, conserved RBS present on both H1 SI-06 and rs H4 NB-10 making variable 
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peripheral contacts. While the heterologous immunization elicited a comparable number of 
antibodies competing with CH67, 5 of 6 antibodies competed on both H1 SI-06 and rsH4 
NB-10 beads suggesting that these antibodies engage the minimal grafted RBS epitope, 
shared between the two HAs. These data point to qualitative differences between antibodies 
elicited by the two immunization regimens. To further characterize these potential 
differences, we asked whether there was a difference in breadth of binding to historical H1 
HAs. We selected a representative antibody from each immunization group (Ab18: 
homologous; Ab144: heterologous immunization) to recombinantly express and to test for 
binding to an HA panel. Figure 5b shows binding data this HA panel using Fabs and 
monomeric HA heads to avoid any avidity effects obtained from IgGs and trimeric HA 
FLsE. Ab18 bound only to the immunizing strain H1 SI-06 with modest affinity. However, 
Ab144 bound to H1 SI-06, rsH4 NB-10 as well as to four additional historical H1 HAs with 
high affinity. Additionaly, we obtained structural information of antibody Ab133 from the 
heterologous immunization that is clonally-related to Ab144 (Fig. 5A and S9C) by negative 
stain EM. The EM 2D class averages show that the antibody binds to the RBS, in a similar 
way to other HA RBS antibodies26 (Fig. 5C and S9B); a stem-directed mAb FI627 is shown 
in Fig. S9A for comparison. These data suggest that the heterologous immunization with our 
resurfaced immunogens offers an advantage over homologous immunization by eliciting 
antibodies with increased binding breadth; this is most likely a consequence of engaging 
only the conserved RBS epitope shared between the HAs and minimizing variable, 
peripheral contacts.
DISCUSSION
Current influenza research has focused on the development of a universal influenza vaccine. 
Such a vaccine should induce broad immunity a) within seasonal, circulating H1 and H3 
subtypes, b) across subtypes (heterosubtypic) and c) pre-pandemic (e.g., H5, H7). The 
pathway to achieving this broad protection will likely come from eliciting or boosting 
humoral responses to conserved sites on HA such as the RBS and “stem”. Immunogen 
design strategies thus far have focused almost exclusively on targeting the conserved stem 
through either selectively displaying the HA2 stem28–31 or using chimeric HAs that present 
circulating H1 or H3 stems with a heterologous HA1 “head”14.
The data presented here show an alternative strategy for candidate immunogens to focus the 
immune response to the broadly neutralizing epitope of the RBS. Grafting of the H1 SI-06 
RBS epitope onto two antigenically distinct HA scaffolds exploits the overall architecture of 
the HA protein circumventing the significant challenge in de novo protein scaffold design. 
Through structure-guided engineering, the optimized scaffolds bind a diverse panel of pan-
H1 and H1/H3 cross-reactive RBS antibodies that represent the type of response one might 
wish to elicit by a universal influenza vaccine. Collectively, the bnAbs in the panel (Table 1) 
bind all H1 isolates both pre-pandemic (<2009) and post-pandemic (>2009) as well as 
circulating H3N2 influenzas. Importantly, this collection of RBS-directed bnAbs tolerate the 
heterologous peripheries of the scaffolds surrounding the graft. These immunogens, 
therefore, would stimulate affinity maturation to refine humoral responses to the conserved, 
RBS core contacts shared between the scaffolds while adapting and accommodating 
antigenically distinct peripheries.
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Our in vivo mouse immunization studies compared the resulting serum and GC responses 
from mice primed and boosted with either homologous or heterologous HA immunogens. 
Despite no discernable difference in a competition assay with bulk serum and a standard 
RBS-directed CH67 mAb, we noted that the heterologous immunization elicited more robust 
GC B cell responses, owing either to the influx of new, H4-specific clones and/or recall of 
the H1 RBS-specific memory B cells. Using single-cell isolation, we noted that in the 
heterologous immunization regimen, very few B cells that were derived from secondary GCs 
reacted with the grafted RBS; consistent with a recent study on the frequency of memory B 
cell reentry to GCs32. We did, however, note that the antibodies elicited by the heterologous 
immunization bound to both the wild-type H1 SI-06 (from which the graft is derived) and 
the resurfaced HAs, indicating that they engage only the minimal, conserved RBS that 
minimize, variable peripheral contacts. Consistent with this hypothesis, a representative 
antibody from the heterologous immunization had broader binding breadth to historical H1 
HAs than did a representative antibody from the homologous control group. Although 
further studies involving fate labeling antigen-experienced cells and single-cell sequencing 
coupled with serum deconvolution will be necessary to better understand GC reentry and 
devise more optimal boosting strategies, our data highlight the benefit of boosting with the 
resurfaced HA to augment the quality of RBS-directed antibodies and mitigate strain-
specific responses.
A significant hurdle for the development of a universal influenza vaccine is preexisting 
immunity present in the human population either through repeated seasonal vaccination or 
influenza infection. The HA scaffolds derived from avian influenzas that, to date, have not 
circulated in the human population and thus would likely avoid boosting strain-specific, 
memory recall responses in immune-experienced individuals. The strategy described here 
could be used to direct naïve immune responses to the conserved RBS through a prime-boost 
vaccine approach and/or could boost subdominant RBS-directed bnAbs already present in 
immune-experienced individuals11,19. More generally, the immunogen design approach of 
epitope grafting could be used for other rapidly evolving pathogens for which preexisting 
immunity is present (e.g., RSV and dengue).
METHODS
Expression and purification of HA
rHA1 “head” and rHA full length soluble ectodomains (FLsE) constructs were cloned into 
pFastBac vector for insect cell expression (Hi5 cells) or pVRC vector for mammalian 
expression (HEK293F cells). HAs were derived from the following templates: A/America 
black duck/New Brunswick/00464/2010 (H4N6) (GenBank: AGG81749.1) and A/mallard/
Wisconsin/10OS3941/2010 (H14N6) (GenBank: AGE03043) (Table S3). All constructs 
were confirmed by DNA sequencing at the DNA Sequencing Core Facility at Dana Farber 
Cancer Institute. For biolayer interferometry (BLI) and crystallography the HA1 head 
constructs contained an HRV 3C-cleavable C-terminal His6X tag or SBP-His8Xtag. The HA 
FLsE constructs used in ELISA assays contained a thrombin or HRV 3C-cleavable C-
terminal foldon tag with either a His6X or SBP-His8Xtag. All constructs were purified from 
supernatants by passage over Cobalt-TALON resin (Takara) followed by gel filtration 
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chromatography on Superdex 200 Increase (GE Healthcare) in 10 mM Tris-HCl, 150 mM 
NaCl at pH 7.5. For BLI and crystallography the tags were removed using HRV 3C protease 
(ThermoScientific) and the protein repurified using Cobalt-TALON resin to remove the 
protease, tag and non-cleaved protein.
Fab and IgG expression and purification
For Fab and IgG production the genes for the heavy- and light-chain variable domains were 
synthesized and codon optimized by Integrated DNA Technologies and subcloned into 
pVRC protein expression vectors containing human heavy- and light-chain constant 
domains, as previously described (11, 19). Heavy-chain constructs for Fab production 
contained a non-cleavable His6X tag; for IgG heavy constructs there was no cleavable 
purification tag. Constructs were confirmed by sequencing at the DNA Sequencing Core 
Facility at Dana Farber Cancer Institute. Fabs and IgGs were produced by transient 
transfection in suspension 293F or adherent HEK 293T cells using Lipofectamine 2000 
(Invitrogen) or polyethylenamine (PEI). Supernatants were harvested 4–5 days later and 
clarified by centrifugation. Fabs were purified using Cobalt-TALON resin (Takara) followed 
by gel filtration chromatography on Superdex 200 Increase (GE Healthcare) in 10 mM Tris-
HCl, 150 mM NaCl at pH 7.5. IgGs were purified using Protein G Plus Agarose 
(ThermoFisher Scientific). Briefly, IgG supernatants were incubated overnight with agarose 
slurry, eluted with 0.1M glycine, pH 2.5, normalized with 1M Tris-HCl, pH 8.0 and dialyzed 
against PBS buffer overnight.
Crystallization and Data Collection.
rsH4NBv1 HA1 head domain and K03.12 Fab (both expressed in HEK293F cells) were 
incubated at 1:1.5 molar ratio, respectively. The complex was isolated by size exclusion 
chromatography using a 24 mL Superdex Increase equilibrated in 10 mM Tris-HCl, 150 mM 
NaCl. Crystallization was achieved by hanging drop vapor diffusion at 18°C. Crystals were 
grown in 100 mM sodium citrate (pH 4.5), 20% (wt/vol) PEG 4000. Crystals were 
cryoprotected in mother liquor supplemented with 25% (vol/vol) glycerol and flash-frozen 
in liquid nitrogen. Data were collected at 0.999 Å with a rotation of 1° per image on the 
8.2.2 beamline, Advanced Light Source, at Berkeley National Laboratory.
Structure Determination and Analysis.
X-ray diffraction data were processed with XDS33.The structure was determined by 
molecular replacement using PHASER34, 35 with the K03.12-A/Texas/50/2012 (H3N2)-head 
complex (PDB ID 5W08) as a search model23. Density-modified, NCS-averaged electron 
density maps were generated with DM (CCP4) and were used as a guide for model building. 
Individual coordinate and group B factor refinement was performed using PHENIX36. 
Model building was done in COOT37 and assessed with MolProbity38. N-linked glycan 
stereochemistry was validated with Privateer39. Figures were generated using PyMOL 
Molecular Graphics System (v1.8.0.0; Schrödinger LLC).
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Purified SI-06 FLsE trimer was incubated with a 6-fold molar excess of FI6 Fab at 4 °C for 
1 h and run over a Superpose 6 Increase (GE Healthcare) in a buffer of 5 mM HEPES, pH 
7.5, 150 mM NaCl. Size exclusion chromatography was not run with Ab133 for initial 
imaging, to prevent Ab133 from dissociating. To keep Ab133 bound, we cross-linked by 
addition of 0.5% glutaraldehyde (GLA; Electron Microscopy Sciences) at 4 °C for 1 hour, 
after which the reaction was stopped by addition of 75 mM Tris buffer (pH 7.4) and then run 
over the Superpose 6 Increase column (GE Healthcare). Fractions containing complex were 
concentrated to 0.01 mg/mL. A 2.5 μl aliquot of the complex was applied for 30 s onto a 
carbon-coated 400 Cu mesh grid that had been glow discharged at 5 mA for 2 min, followed 
by negative staining with 0.7% uranyl formate for 20 s. Samples were imaged using a FEI 
Tecnai T12 microscope operated at 100 kV and a magnification of ~52,000, yielding a pixel 
size of 1.66 Å at the specimen plane. Images were acquired with a Gatan 4k × 4k OneView 
camera using a nominal defocus of 1500 nm at 0°. Particles were picked with EMAN2 and 
put into a particle stack.
Interferometry binding experiments
Interferometry experiments were performed using a BLItz instrument (fortéBIO, Pall 
Corporation). Fabs were immobilized on a Ni-NTA biosensor and cleaved rHA heads (made 
in insect Hi5 cells) were titrated to obtain binding affinities. Initial, single-hit concentrations, 
were tested at 35μM for binding and then subsequent titrations for at least three different 
concentrations (chosen depending on the apparent KD from the high concentration); the 
refined KD was obtained through global fit of the titration curves by applying a 1:1 binding 
isotherm using vendor-supplied software. All experiments were performed in 10 mM Tris-
HCl, 150 mM NaCl at pH 7.5 and at room temperature.
ELISA
5–10ng of rHA FLsE expressed in insect Hi5 cells were adhered to high-capacity binding, 
96 well-plates (Corning) overnight in PBS. Plates were blocked with non-fat dried milk in 
PBS containing Tween-20 (PBS-T) for 1hr at room temperature (RT). Blocking solution was 
discarded and 10-fold dilutions of RBS-directed IgGs in PBS were added to wells and 
incubated for 1hr at RT. Plates were then washed three times with PBS-T. Secondary, anti-
human IgG-HRP (Abcam), in PBS-T was added to each and incubated for 1hr at RT. Plates 
were then washed three times with PBS-T. Plates were developed using 1-Step ABTS 
substrate (ThermoFisher) and immediately read using a plate reader at 410nm. Data were 
plotted using Prism 8 (GraphPad Software) and affinities determined by applying a 
nonlinear regression model.
Mice
C57BL/6 mice were obtained from the Jackson Laboratory. JH6 mice were generated as 
described below. Mice were bred and maintained under specific pathogen-free conditions at 
the Duke University Animal Care Facility. Mouse immunization experiments were 
conducted per the approved IRB protocol by the Duke University Institutional Animal Care 
and Use Committee.
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Generation of human JH6 murine model
In the human JH6 mouse model, human JH6 replaces mouse JH1–JH4, and human D2–2 
replaces mouse DQ52 segment. The choice of human JH6 and D2–2 was based on the 
observation that a substantial fraction of human anti-RBS antibodies utilize these gene 
segments in CDR H3. To generate the hJH6 mouse line, a targeting construct containing the 
hD2–2 and hJH6 cassette was transfected into an F1 ES cell line that was derived from a 
cross between the 129/Sv strain and the C57BL/6 strain mice. The cassette was integrated 
into the mouse DQ52-JH6 locus via homologous integration. The homology arm was derived 
from genomic DNA from the C57BL/6 mouse strain. Due to sequence polymorphisms 
between the 129/Sv mouse strain and C57BL/6 strain, homologous recombination 
preferentially integrated the hD2–2 and hJH6 cassette into the IgHb allele in the ES cell. The 
ES clone was injected into mouse Rag2 deficient blastocysts to generate chimeric mice. 
Because Rag2 is essential to V(D)J recombination, all the B and T cells were derived from 
the injected ES cells, and the chimeric mice can be used directly for analysis. The method is 
referred to as Rag2 deficient blastocyst complementation40. Fig.S7 shows analysis of the B 
cells in this type of chimeric mice, as compared with a WT control mouse of mixed 129/Sv 
and C57BL/6 genetic background. For this analysis, splenic B cells were stained with 
fluorophore conjugated antibodies, as indicated next to the FACS plots. To analyze the VH, 
D and JH usage in the Ig heavy chains from IgMb B cells (Table S2), IgMb B cells were 
sorted by FACS, and 5’RACE was performed to generate a library of μ heavy chains 
expressed by the sorted B cells. The PCR products were cloned into pGEXT-easy vector, 
and some of the cloned PCR products were sequenced. The identities of the VH, D and JH 
segments were determined by Ig Blast.
Immunizations
JH6 mice (female, 8 to 12-week-old) were immunized with 20 μg of H1 SI-06 HAs, 
expressed in insect Hi5 cells, in Alhydrogel® via footpad. Eight weeks later, cohorts of mice 
were boosted with 20 μg of either H1 SI-06 HAs or rsH4NBv3 HAs in Alhydrogel® via 
hock. Mice were sacrificed 8 days after prime or boost immunizations, respectively, and the 
draining, popliteal lymph nodes and sera were collected to measure GC and antibody 
responses, respectively.
Flow Cytometry
GC B cells (GL-7+B220hiCD38loIgD−CD93−CD138−) and plasmablasts/-cytes 
(B220loCD138hi) cells in popliteal LNs were determined as described41, 42. Labeled cells 
were analyzed/sorted in a FACS Canto (BD Bioscience) or a FACS Vantage with DIVA 
option (BD Bioscience). Flow cytometric data were analyzed with FlowJo software (Treestar 
Inc.). Doublets were excluded by FSC-A/FSC-H gating strategy. Cells that take up 
propidium iodide were excluded from our analyses.
Nojima Culture
Single B cell cultures were performed as described42. Briefly, single GC B cells were sorted 
for their phenotype and cultured for 10 days in the presence of NB-21.2D9 feeder cells. 
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After culture, the supernatants were harvested for Luminex assays and culture plates were 
stored at −80°C for V(D)J amplifications.
BCR sequencing
V(D)J rearrangements of cultured B cells were amplified by a nested PCR, cloned, and 
sequenced as previously described42. The rearranged V, D, and J gene segments were 
identified using IMGT/V-QUEST (http://www.imgt.org/).
Luminex multiplex assay
Reactivity of clonal IgGs in culture supernatants and of mouse sera was determined by 
Luminex multiplex assay with modifications41. Briefly, mixtures of antigen-conjugated (H1 
SI-06 or rsH4NBv3 HAs, both FLsE, made in insect Hi5 cells) microspheres were incubated 
with serially diluted serum samples for 2 hours at room temperature or overnight at 4°C (for 
competition assay) with mild agitation. Samples were diluted in PBS containing 1% cow 
milk, 1% BSA, 0.05% Tween 20 and 0.05% NaN3. For competition, human monoclonal 
IgG1 CH67 (2 ng/ml) was added to the plates without washing and plates were incubated for 
2 hours at room temperature with mild agitation. After washing, PE goat anti-mouse IgG or 
PE mouse anti-human IgG (both from Southern Biotech, the latter for competition assay) 
was added to the plates and incubated for 1 hour at room temperature with mild agitation. 
After washing, microspheres were resuspended in PBS containing 1% BSA, 0.05% Tween 
20 and 0.05% NaN3 and fluorescent signals from each microsphere were measured in a Bio-
Plex® 3D machine (Bio-Rad).
Data Availability
Coordinates and structure factors have been deposited in the Protein Data Bank under 
accession code PDB 6UR5 for the rsH4NBv1-K03.12 complex.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: RBS grafts and sequence alignments.
A, Phylogeny of influenza subtypes. Group 1 and 2 influenzas are annotated. Highlighted in 
pink are the seasonal subtypes currently circulating in the human population. B, 
Representative H1 antigenic clusters: H1 Massachusetts/1/1990 (MA-90), H1 Solomon 
Islands/03/2006 (SI-06) and H1 California/07/2009 (CA-09) are listed. Sequence alignment 
is in reference to SI-06 and conserved residues are marked as (.); segments defining the H1 
RBS graft, S1–4, are colored. C, Residues comprising S1–4 of the acceptor scaffolds (H3 
numbering) from non-circulating influenzas H4 New Brunswick/00464/2010 (H4 NB-10), 
H6 Wisconsin/617/1983 (H6 WI-83), H14 Wisconsin/10OS3941/2006 (H14 WI-06) and 
H16 Delaware Bay/296/1998 (H16 DB-98). D, Influenza HA trimer (PDB 5UGY) in surface 
representation. HA1 is in silver, HA2 in dark gray and S1–4 are colored. e, LSTc 
(sialylneolacto-N-tetraose c, stick representation) modeled in complex with HA. S1–4 is 
colored and HA is in silver.
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Figure 2: Structure of K03.12 in complex with rsH4NBv1 and scaffold improvement.
A, Antibody K03.12 Fab (heavy and light chains are colored blue and green, respectively) in 
complex with rsH4NBv1 HA1 “head” (silver). The CDR H3 (magenta) is marked. B, Close-
up of the antigen-binding site. The CDR H3 (magenta) is shown in sticks with key 
interacting HA residues (silver). Hydrogen bonds are denoted in yellow, dashed-lines. C, 
Comparison of the RBS of H1 SI-06, yellow, (PDB 4YJZ), H4 A/duck/Czechoslovakia/1956 
(H4 CZ-56), black (PDB 5XL3) and rsH4NBv1, silver. The segments of the grafts are 
labeled and colored. D, rsH4NBv2 and e, rsH4NBv3 with residues changed for each 
construct represented by a colored sphere. The original, unchanged segments from 
rsH4NBv1 are labeled and colored.
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Figure 3: Reactivity of RBS-directed IgGs for rsHAs.
CH67 (blue), H2526 (red), H2227 (green), 641 I-9 (violet) and K03.12 (orange) IgGs were 
titrated against A, wildtype H4 NB-10, B, rsH4NBv1, C, rsH4NBv2, D, rsH4NBv3, E, KDs 
obtained from curves in A-D for H4 constructs displayed as a “heatmap”: warm colors are 
high affinity and cool colors low affinity. The legend is in M. IgG titrations for F, wildtype 
H14 WI-10, G, rsH14WIv1, H, rsH14WIv2 and I, control H1 SI-06 HA constructs. J, KDs 
obtained from curves in F-I for H14 constructs. ELISA measurements were done in 
duplicate over the concentration range except for A, and F, where only 1μM final 
concentration of IgG was tested. The wildtype H1 SI-06 values in E and J are both derived 
from I. Curve fitting was done with a nonlinear regression model and KDs were determined 
using GraphPad Prism version 8.0.
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Figure 4: in vivo assessment of rsHA immunogenicity.
A, schematic representation of the immunization strategy B, CH67 competition to H1 SI-06 
FLsE HA against the sera from wild-type non-immunized B6 mice (black), JH6 mice primed 
and boosted with H1 SI-06 (blue) and mice primed with H1 SI-06, then boosted with 
rsH4NBv3 (pink), C, total GC B cell counts in the animal cohorts. n=4 mice for B6 and n=4 
mice for JH6. *p < 0.05, Welch’s t test. Error bars represent SD, D, serum reactivity against 
H1 SI-06, e, serum reactivity against rsH4NBv3. The mean values are plotted for d and e 
with error bars indicating SD.
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Figure 5: Identification and biochemical characterization of RBS-directed antibodies.
A, CH67 competition experiment against the single B cell culture supernatants from 
homologous (H1 SI-06; blue) and heterologous (H1 SI-06, rsH4NBv3; pink) immunizations. 
The competition was performed on Luminex beads coated with either H1 SI-06 or with rsH4 
NB-10, antibody competition is expressed as % inhibition (x-axis); antibodies with >75% 
inhibition are colored. Representative monoclonal antibodies Ab18, Ab133 and Ab144 were 
selected for further characterization. B, Binding to a panel of historical H1 HAs and the 
resurfaced rsH4 NB-10 was assayed with recombinant Fabs using bio-layer interferometry. 
Affinity constants (KDs, in μM) were obtained by applying a 1:1 binding isotherm using 
vendor-supplied software. The “heatmap” color scheme is a visualization aid: warm colors 
are high affinity and cool colors low affinity. H1 SI-06 – A/Solomon Islands/03/2006, H1 
USSR-77 – A/USSR/90/1977, H1 MA-90 – A/Massachusetts/1/1990, H1 FL-93 – A/
Florida/2/1993, H1 BE-95 – A/Beijing/262/1995, H1 NC-03 – A/North Carolina/3/2003, 
rsH4 NB-10 - resurfaced duck/New Brunswick/00464/2010; N.D. – non-detectable. C, 
Visualization of the HA-Ab133 complex by negative stain electron microscopy. The top 
panels are of HA alone with and without crosslinking to Ab133 with glutaraldehyde. Ab133 
is colored green in the bottom right panel and compared to an RBS antibody bound to HA 
(PDB ID: 5UG0). One copy of the RBS antibody is not shown for clarity.
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Table 1.
Affinity measurements of rsHAs to a panel of RBS-directed Abs.
KDs (in μM) were obtained by applying a 1:1 binding isotherm using vendor-supplied software with at least 
three independent concentrations. The VH gene usages are listed for each antibody. KDs beyond the limit of 













H1 SI-06 0.57 0.67 0.56 0.39 0.83 1.1
H4 NB-10 >100 >100 >100 >100 >100 >100
H14 WI-10 >100 >100 >100 >100 >100 >100
rsH4NBv1 >100 >100 >100 >100 4.3 >100
rsH4NBv3 1.6 17.7 0.93 0.67 0.65 0.34
rsH14WIv1 9.5 >100 >100 >100 2.2 1.4
rsH14WIv2 0.31 2.7 0.20 1.0 1.1 0.065
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